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Dosing performance of dry powder inhalers is dependent on patient’s inspiratory effort. This study compares the
inhalation profiles generated by patients with severe obstructive lung disease using DiskusTM and TurbuhalerTM
inhalers. The patient profiles are subsequently used to determine the dosing performance of fluticasone propionate
DiskusTM and budesonide TurbuhalerTM inhalers.
Inhalation profiles were recorded in COPD patients (FEV1 30% predicted) as they inhaled with maximal effort
through the inhalers. The profiles were used in an inhalation simulator to assess the dosing performance by
measuring the total emitted dose and the fine particle mass for each inhaler type.
Peak inspiratory flow was significantly higher through the DiskusTM (mean 82?3 lmin71) compared with
TurbuhalerTM (mean 53?5 lmin71, difference = 28.8 lmin71; P50?0001). In addition, in direct comparison of the
two devices, the DiskusTM was shown to deliver a more consistent dose irrespective of flow than the TurbuhalerTM
in this patient population. These findings may be of importance in optimising selection of devices for patients with
severe airway obstruction.
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It is widely accepted that the best route of administration
for drugs in the treatment of airway obstruction, including
asthma and chronic obstructive pulmonary disease
(COPD), is by inhalation. The clinical effect of inhaled
therapy depends on the lung dose, its particle size
distribution, the patients’ inspiratory flow, inhaled volume
and degree of airways obstruction (1, 2).
The pressurized metered dose inhaler (pMDI) is the most
commonly prescribed inhaler but some patients find it
dicult to use as it requires the patient to co-ordinate
actuation of the device with inhalation of the drug (3–5).
This can be overcome by the use of a spacer. Breath-
operated devices including dry powder inhalers (DPIs)
reduce the requirement for patient co-ordination and as
such can be simpler to use than MDIs. This is an advantage
for some patients, for example adults with co-ordinationReceived 27 September 2000 and accepted in revised form 16
January 2001.
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removes the dose from a DPI (6) and generates a negative
pressure (or pressure drop) across the inhalation device that
is proportional to the applied flow (7). The inhalation flow
has been shown to have an effect on the dose delivery and
lung deposition of certain dry powder inhalers, particularly
those with a high internal resistance and complex flow path,
such as TurbuhalerTM (8–13). The data show a tendency for
lower flows to result in reduced dosing and lower
deposition with such devices. It is important therefore to
be aware of the flow rates and the nature of inhalation
profiles that different groups of patients can generate
through different devices.
COPD treatment is changing to incorporate the use of
inhaled corticosteroids (14) as well as anti-cholinergics and
short-acting b2 -agonists. This study therefore evaluates the
in-vitro performance of DiskusTM and TurbuhalerTM inha-
lers containing the corticosteroids fluticasone propionate
and budesonide respectively, using inhalation flow profiles
obtained from patients to generate the doses from the
inhalers.
The DiskusTM inhaler is a multi-dose powder inhaler,
which delivers accurate doses of drug to the patient from
pre-dispensed, hermetically-sealed blisters. It is easy to use,
has a dose counter and contains 1 month’s therapy for a
patient taking standard maintenance doses (15). The# 2001 HARCOURT PUBLISHERS LTD
FIG. 1. Schematic for measurement of pressure drop/time
and flow rate/time profile during inhalation, showing the
modifications to the device, the air-tight box for blinding
and the output to the IPR.
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drug is delivered from a bulk powder reservoir containing
100 doses (16). This device incorporates a metering unit fed
from the drug reservoir, which is charged by the patient
twisting the base of the device immediately prior to
inhalation.
The performance of these two devices has been exten-
sively studied in vitro usually by comparison using standard
air flow rates from pumps. The development of an
inhalation profile recorder (IPR) has enabled the inhalation
flow profiles from individual patients to be collected using
both devices. These profiles are then used in the electronic
LungTM device (ELD), an inhalation simulator (17,18), to
draw doses from both the DiskusTM and TurbuhalerTM
inhalers and assess the particle size distribution of the active
drug using a cascade impactor. The total emitted dose
(TED) and fine particle mass (FPM) may also be
calculated. The FPM, which is the mass of drug considered
capable of reaching the lungs, is usually defined as the
amount of drug with a particle size less than 6mm.
This methodology has already been used to assess the
characteristics of the dose emitted from the fluticasone
propionate DiskusTM inhaler and the budesonide Turbu-
halerTM inhaler, in terms of mass and size distribution,
using inhalation profiles from paediatric asthma patients
(19). The primary objective of this study was to obtain
flows from patients with severe COPD when inhaling
through the DiskusTM and TurbuhalerTM respectively. The
breathing simulator will then be used to mimic the flow
profiles and obtain data on the dose delivery characteristics
from the two inhalers.
Materials and methods
Inhalation profiles from patients with severe airways
obstruction were collected using the IPR. In order to
collect these profiles, a DiskusTM and TurbuhalerTM inhaler
were each modified to enable the pressure drop across the
device and flowrates developed during inhalation to be
recorded. Subsequently, the in-vitro dosing performance of
two batches of marketed DiskusTM and TurbuhalerTM
inhalers was evaluated using the same patient inhalation
profiles in the ELD.
INHALATION PROFILE RECORDER
The inhalation profiles were recorded using an IPR for both
devices. This is a PC-based data logging system, which
allows the pressure generated during an inhalation to be
recorded. In this study, flow rates were also recorded.
MODIFICATION OF DPIS FOR INHALATION
PROFILE MEASUREMENT
Inhalers for measurement of the inhalation profiles were
selected from standard production batches and emptied of
their doses. The pressure drop/flow characteristics were
measured using a calibrated pressure transducer (Solomat513LW) and in-line flowmeter (Scheme VL512). The details
of the method and equipment have been previously
published (18). The mouth-piece of each inhaler was
modified by inserting a length of capillary tubing. Each
device was also enclosed in an airtight box to which a flow-
mesh was added (see Fig. 1). The airtight box had two
purposes: firstly to enable blinding and secondly, for the
attachment of a flow-mesh.
A pressure transducer was attached to the capillary
tubing to allow the measurement and recording of static
pressure developed during inhalation through the device.
The differential pressure across the mesh, as measured by
two other pressure transducers, gave the flows achieved
during inhalation. The same blinded inhalers, each fitted
with disposable mouth-pieces, were used for each patient.
VALIDATION
The pressure drop/flow rate characteristics of the inhalers
used in the clinical study were measured and compared with
samples of inhalers from standard batches; thereby ensur-
ing that their characteristics were unchanged from normal
inhalers after emptying, after fitting a pressure probe and
after enclosing in a box for blinding.
CLINICAL STUDY
This was a single-centre, randomized, double-blind, cross-
over study. Adults with a clinical history of severe COPD
and an FEV1 30% predicted normal were included in the
study. They all had to be able to perform reproducible
forced expiratory and inspiratory manoeuvres to generate
three technically acceptable flow–volume curves. These
were used to obtain the patient’s FEV1, which was also
expressed as a percentage of predicted normal values. The
patients could take any concurrent medication as necessary.
Five of the 18 patients used short-acting b2-agonists alone;
the rest combined bronchodilator therapy with theophyl-
lines (three patients), with inhaled corticosteroids (13
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(three patients). All patients gave informed consent and
appropriate ethical committee approval was obtained prior
to commencement of the study. Both devices were used on
the same day with the order assigned randomly, and both
patient and operator blinded to the device used on each
occasion. Patients were instructed to inhale maximally
through each device. Patients were asked to perform one
manoeuvre with the device and then rested prior to
performing a repeat flow–volume measurement. The
patient was then given the second device as indicated by
the randomisation code.
EX-VIVO DETERMINATION OF PRODUCT
PERFORMANCE
The term ex-vivo has been used to describe data generated
by the combined use of in-vivo parameters with in-vitro
analytical techniques. The inhalation profiles from patients
collected by the IPR were used in an inhalation simulator,
the ELD, to assess the ex-vivo performance of fluticasone
propionate (250 mg dose) DiskusTM inhaler and budesonide
(200mg dose) TurbuhalerTM inhaler.
The primary objective of this study is to determine the
dosing characteristics of the DiskusTM and TurbuhalerTM
inhalers when used by COPD patients. Whilst the 2 : 1
potency ratio between fluticasone propionate and budeso-
nide has been demonstrated in asthma, clinical studies
demonstrating this in patients with COPD are not
available. Therefore it was felt appropriate to test dose
delivery from products which are of the closest match in
terms of label claim, rather than confound the data by
comparing unequal dose products.
The pressure drop/flow characteristics of these inhalers
were measured to compare with standard batches forFIG. 2. The Electronic LungTM device.validation and to input into the ELD. The detailed method
used for assessing ex-vivo performance using the ELD has
been published previously (18).
THE ELECTRONIC LUNGTM DEVICE
The ELD (Fig. 2) comprises a computer-controlled piston
that replicates the subjects profile from the IPR. The dose is
drawn as an aerosol cloud from the inhaler into a sample
chamber and a feedback system allows the ELD to monitor
and adjust, if necessary, the work done by the piston to
match the required pressure drop. At the end of the
inhalation, valves are switched to isolate the inhaler and to
enable the evacuation of the sample chamber by drawing
air at 28?3 lmin71 through an Andersen Mark II cascade
impactor by an auxiliary pump. A number of doses, as
defined by the requirements of the analytical methods, are
‘inhaled’ in turn from the inhaler into the ELD. At the end
of the inhalations, the inhaler is detached from the ELD
and all surfaces in the system, which have been exposed to
the dose, are rinsed with a suitable solvent. The solutions
from the throat, sample chamber, side filter (piston
chamber) and various stages of the Andersen cascade
impactor are then analysed by high performance liquid
chromatography assay and the TED and FPM of the drug
is calculated using validated methods. The TED is a
measure of the drug removed from the device during
inhalation. The FPM is an in-vitro prediction of the
amount of drug from the total emitted dose that may
reach the lung. In this study, this has been defined as
the mass of particles in the size range 0?43 – 5?8mm, since
this relates to the mass of drug deposited on stages 2–7 of
the Andersen cascade impactor when operated at
28?3 lmin71.
TABLE 1. Details of 17 patients in the study (12 males,
five females)
Mean Range
Age (years) 60?4 45–73
FEV1 (l) 0?67 0.42–0.92
FEV1 (% predicted) 22?6 15–30
Duration of airways
obstruction (years)
51 0
1–5 4
6–10 5
410 8
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The statistical analysis used for comparison of dosing
performance is described elsewhere by Jones and Kenward
(20). Two-sample t-tests were used to investigate whether
the order in which the devices were used affected the results,
and whether there was a carry-over effect. Subsequently, a
paired t-test was used to compare device means and
Levene’s test (21) was used to compare the variability of
results from the devices. The three variables of interest were
peak inspiratory flow rate (PIFR), TED and FPM.
Results
VALIDATION OF INHALERS
Figure 3 shows the pressure/flow characteristics of the
inhalers used to collect inhalation profiles from the patients,
and compares them to standard inhalers. No differences
were shown between the test inhalers and the standard
batch samples.
PATIENT DATA
The intent-to-treat population consisted of 18 patients.
However one patient was not included in the statistical
analysis as his technique when breathing through the
devices was inadequate. Details of the patients are given in
Table 1.FIG. 3. Effect of modifications on the pressure drop profile
of DiskusTM and TurbuhalerTM devices. Unmodified
DiskusTM (o), DiskusTM blinded with presses probe (*),
TurbuhalerTM blinded with pressure probe (~),
unmodified TurbuhalerTM (~).
FIG. 4. Typical inhalation profiles from DiskusTM (—) and
TurbuhalerTM (- - -) inhalers, with COPD patients. The
shape, maximal and minimal pressure drop values for
both inhalers are similar but the PIFR for the same
pressure drop is higher for DiskusTM inhaler because of its
lower resistance.INHALATION PROFILES
Figure 4 shows representative examples of inhalation
profiles recorded from this study for DiskusTM and
TurbuhalerTM inhalers. The profiles illustrated are from
the patients in this study who achieved the highest and
lowest PIFR (or pressure drop).
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recorded from this study. The PIFR was measured for each
device. The mean PIFR through the DiskusTM
(82?3lmin71) was significantly greater than that through
the TurbuhalerTM (53?5lmin71) (P50?0001). The adjusted
mean peak pressure drop observed in the present study for
the DiskusTM was 3?5 kPa, which was significantly less
(P=0.019) than for the TurbuhalerTM (4?0 kPa).
ANALYTICAL RESULTS
The TED and FPM results for all inhalers used in the dose
performance testing are summarized in Table 3. The results
are expressed in micrograms and as a percentage of label
claim (% label), to allow direct comparison between
different strength products. A statistical comparison of
the standard deviations of the results, and the differences in
the mean values was carried out to determine the consi-
stency and accuracy of dosing for each type of inhaler
tested.
TED for fluticasone propionate DiskusTM inhaler is close
to the % label claim. The TED, expressed as % label, from
the DiskusTM inhaler is significantly higher than that from
the budesonide TurbuhalerTM inhaler (P50?0001). The
mean TED values are 95.3% label claim and 68.1% label
claim for DiskusTM inhaler and TurbuhalerTM inhaler,
respectively. The variability associated with TED is also
significantly less for the DiskusTM inhaler than for the
TurbuhalerTM inhaler (P50.0001).
The FPM from fluticasone propionate DiskusTM inhaler
is significantly higher (P=0?0101) and less variable
(P=0?006) than for the budesonide TurbuhalerTM inhaler.TABLE 2. Summary inhalation profile data
Product Peak pressure
drop (kPa)
Peak inspiratory
flow rate (lmin71)
Mean Range Mean Range
DiskusTM inhaler 3?5 1?1–6?3 82?3 46?1–115?3
TurbuhalerTM inhaler 4?0 1?5–6?9 53?5 32?7–73?0
TABLE 3. Summary of dose performance data
Product
Mean
Fluticasone propionate mg 238?2
DiskusTM inhaler 250 mg % labelled dose 95?3
Budesonide TurbuhalerTM mg 136?2
inhaler 200 mg % labelled dose 68?1The mean FPM values are 17?5% label claim and 13?5%
label claim for DiskusTM inhaler and TurbuhalerTM
inhaler, respectively.
Figure 5(a) and (b) are plots of TED and FPM
(expressed as % label claim), respectively vs. PIFR. The
gradient of the trend line for each data set is a measure of
the dependence of the dose on the flow rate. Low gradients
for the DiskusTM inhaler show that the TED and FPM
are independent of the PIFR. In contrast, the Turbuha-
lerTM inhaler data sets, with higher gradients, show
a greater degree of flow dependence for both TED and
FPM.
Discussion
Ideally, an inhaler should deliver a dose of drug accurately
and consistently. This study demonstrates that elderly
patients with severe COPD are able to achieve high
inspiratory flows from the DiskusTM inhaler. TED and
FPM from the DiskusTM inhaler were consistent and close
to the label claim, irrespective of the inhalation flow profile.
In contrast, for the TurbuhalerTM inhaler, the TED and
FPM, as % label claim, were lower and more variable.
The data from this study are similar to those in previous
studies. In a previous in-vitro comparison between salme-
terol DiskusTM and terbutaline TurbuhalerTM inhalers at
fixed flow rates of 30, 60 and 90 lmin71, the DiskusTM
inhaler demonstrated more accurate and reproducible
dosing throughout the life of the inhaler than the
TurbuhalerTM inhaler (22). A similar conclusion was drawn
in another study comparing fluticasone propionate Dis-
kusTM and budesonide TurbuhalerTM inhalers (23), where
the inhalers delivered 87–93% and 40–58% of label claim
dosage, respectively. A high degree of variability has also
been shown within a batch, and between batches, of
TurbuhalerTM inhalers (24, 25). The data are also consis-
tent with previous findings, suggesting higher resistance
within the TurbuhalerTM than the DiskusTM (19, 26). The
devices also differ in that the TurbuhalerTM is a reservoir-
based system, while the DiskusTM uses the concept of
factory-dispensed microgram doses of drug blended with
lactose and loaded as individual units in a foil strip (16,15).
The foil strip provides advantages of moisture protection
and dose integrity up to the point of use by the patient.TED FPM
Range SD Mean Range SD
217?9–264?1 43?8 25?6–58?4
87?2–105?7 3?8 17?5 10?2–23?4 3?2
114?6–157?5 27?0 6?6–42?6
57?3–78?8 8?0 13?5 3?3–21?3 6?0
FIG. 5. Dosing performance of DiskusTM and
TurbuhalerTM inhalers. (a) TED (% label claim) vs.
PIFR; (b) FPM (% label claim) vs. PiFR Fluticasone
DiskusTM (^); Budesonide TurbuhalerTM (&).
EX-VIVO PERFORMANCE OF DISKUSTM AND TURBUHALERTM INHALERS USING INHALATION PROFILES FROM COPD PATIENTS 329The results of Bisgaard et al. (19) in asthmatic children
showed a similar trend to ours, mean PIFR were measured
for 4- and 8-year-olds, respectively, as 70, 105 lmin71 for
DiskusTM inhaler and 53, 76 lmin71, for TurbuhalerTM
inhaler. The present study showed a significantly higher
PIFR for the DiskusTM inhaler than the TurbuhalerTM
(P50?0001). This is in agreement with a study by
Conway et al. (26), who found significantly higher peak
pressure drops for TurbuhalerTM inhaler, and lower
inspiratory flows in a group of adult and paediatric
asthmatics.
Determining the dosing characteristics of inhalers by
testing in vitro at fixed flow rates does not accurately
represent how patients inhale through a device in vivo.
The ELD (18), an inhalation simulator, was developed
to separate the generation of the inhalation aerosol at
varying flow rates, similar to a patient’s inhalation, from
the dose performance testing process, which necessarilyuses fixed flow rates. Bisgaard et al. applied this method
first to paediatric asthmatics (19). In an ex-vivo study
similar to this, inhalation profiles were recorded from
18 asthmatic children aged 4 and 8 years of age who
were well controlled and well trained in both devices.
The profiles were used with the ELD to assess the
dosing performance of fluticasone propionate DiskusTM
inhaler and budesonide TurbuhalerTM inhaler. The results
showed similar trends to this study: namely that the
DiskusTM inhaler produced a significantly higher TED
and greater consistency in terms of TED and FPM than
the TurbuhalerTM inhaler. However, in the study by
Bisgaard et al. it was shown that in terms of fine
particle fraction, the mean value was greater from the
TurbuhalerTM inhaler compared with the DiskusTM in-
haler, although the variability for TurbuhalerTM inhaler
was significantly greater.
These differences may be due to the use of a relatively
coarse grade of lactose, which acts as a diluent and
aerosolization aid in the fluticasone DiskusTM inhaler
formulation, compared to the drug only budesonide
formulation in the TurbuhalerTM inhaler. The coarse
lactose in the DiskusTM formulation aids in accurate
metering and ease in aerosolization. It also has a tendency
to reduce the proportion of very fine (52 mm) parti-
cles, which may be beneficial when trying to reduce
delivery to the systemic circulation. Budesonide in the
TurbuhalerTM inhaler is agglomerated into large spheres,
which require energy to aerosolize and further energy to
de-aggregate into respirable particles. The energy input
tends to generate more fine particles, particularly those
less than 2 mm in size, which may be of less therapeutic
benefit.
The relationships between flow-dependent dose delivery,
lung deposition and clinical effect are not clear. In a recent
clinical study (27), salmeterol given by the DiskusTM at an
inhalation flow rate of either 30 or 90 lmin71 had a similar
broncho-protective effect against exercise challenge at 12 h.
In contrast, formoterol given by the Aeroliser, a flow-
dependent device, had a greater protective effect at 12 h
when inhaled at a high flow, compared with inhalation at a
low flow. These data would suggest that flow-dependent
dose delivery might be of clinical relevance.
MDIs remain the most widely prescribed device in
COPD. However, low resistance DPIs which can be used
with a minimal inspiratory effort, and provide consistent
dosing, may offer an alternative in this population with
compromized lung function. Furthermore, for inhaled
corticosteroids, consistent dosing is arguably more impor-
tant than for b-agonists, to ensure better dose titration and
allow use of a truly minimal effective dose, hence
maximising the therapeutic ratio of the product and
reducing the potential for systemic side-effects associated
with chronic long-term therapy.
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